The Pharma Letter1d
Phase IV Ingrezza data move focus from sales outlook
Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that ...
Neurocrine reports patient-reported outcome data from KINECT-PRO study
Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...
IRLAB Therapeutics: IRLAB Publishes Phase IIb Data on Mesdopetam in Movement Disorders Clinical Practice
GOTHENBURG, SWEDEN / ACCESS Newswire / February 27, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, February 27, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a compa ...
Assessing Neurocrine Biosciences: Insights From 15 Financial Analysts
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.4, with a high estimate of $190.00 and a low estimate of $147.00. This current average ...
IRLAB Receives Positive Feedback from EMA Confirming Alignment with FDA on Phase III Program for Mesdopetam
GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 20 February, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB a company ...
IRLAB Therapeutics: IRLAB Receives Positive Feedback from EMA Confirming Alignment with FDA on Phase III Program for Mesdopetam
GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 20 February, 2025 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB a company d ...
Adelante Valle10d
Assemblyman announces drug-induced movement disorder awareness program bill
Assemblyman Jeff Gonzalez (R-Indio) announced Monday the introduction of AB 641, which would create a public awareness ...
Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January
We recently published a list of 10 Top Insider Stock Buys And Sells In January. In this article, we are going to take a look ...
The Motley Fool18d
Why Neurocrine Biosciences Stock Sank Today
According to reports, Verma cited uninspiring guidance for the company's leading drug, Ingrezza (a treatment for movement disorder tardive dyskinesia). Management proffered guidance for Ingrezza ...
verywellhealth20d
DMAE Benefits, Uses, and Risks
Additionally, it has been used for depression, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, autism, and tardive dyskinesia. Currently, the effects of DMAE aren't ...
Neurocrine price target lowered to $147 from $157 at Wedbush
Wedbush analyst Laura Chico lowered the firm’s price target on Neurocrine (NBIX) to $147 from $157 and keeps an Outperform rating on the ...
Seeking Alpha22d
Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript
Eight years after introducing the first treatment for tardive dyskinesia, we're on track to once again achieve double-digit year-over-year growth this year. While our guidance reflects a moderated ...